BMS-986260
BMS-986260, an immuno-oncology agent, is a potent, selective, and orally active TGFβR1 inhibitor (IC50=1.6 nM) . BMS-986260 displays exquisite selectivity for TGFβR1 over its isozyme TGFβR2, as well as in a panel of more than 200 kinases examined. BMS-986260 inhibits TGFβ mediated nuclear translocation of pSMAD2/3 in MINK and NHLF cells lines with an IC50 of 350 nM and 190 nM, respectively[1].
Product Specifications
CAS Number
2001559-19-7
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
TGF-β Receptor
Type
Reference compound
Related Pathways
TGF-beta/Smad
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/bms-986260.html
Purity
99.95
Solubility
DMSO : ≥ 100 mg/mL
Smiles
N#CC1=CN=C2C=CC(C3=C(C4=CC=C(F)C(Cl)=C4)N=CN3CCO)=NN21
Molecular Formula
C18H12ClFN6O
Molecular Weight
382.78
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Milbemycin Oxime (Mixture of Milbemycin Oxime A3 and Milbemycin Oxime A4, 80:20)
ANKRD56 (SOWAHB) (NM_001029870) Human Over-expression Lysate
